AU6946300A - Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders - Google Patents

Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders

Info

Publication number: AU6946300A
Authority: AU; Australia
Prior art keywords: prevent; dna encoding; bone disorders; metabolic bone; inhibit metabolic
Prior art date: 1999-08-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU69463/00A

Inventor

Patrick M. Doran

Sundeep Khosla

B. Lawrence Riggs

Stephen T. Russel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mayo Foundation for Medical Education and Research

Original Assignee

Mayo Foundation for Medical Education and Research

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-30

Filing date

2000-08-29

Publication date

2001-03-26

2000-08-29 Application filed by Mayo Foundation for Medical Education and Research filed Critical Mayo Foundation for Medical Education and Research

2001-03-26 Publication of AU6946300A publication Critical patent/AU6946300A/en

Status Abandoned legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

AU69463/00A 1999-08-30 2000-08-29 Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders Abandoned AU6946300A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15141599P	1999-08-30	1999-08-30
US60151415		1999-08-30
PCT/US2000/023755 WO2001016299A1 (en)	1999-08-30	2000-08-30	Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders

Publications (1)

Publication Number	Publication Date
AU6946300A true AU6946300A (en)	2001-03-26

Family

ID=22538668

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU69463/00A Abandoned AU6946300A (en)	1999-08-30	2000-08-29	Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders

Country Status (3)

Country	Link
AU (1)	AU6946300A (en)
CA (1)	CA2383043A1 (en)
WO (1)	WO2001016299A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002024896A2 (en)	2000-09-22	2002-03-28	Immunex Corporation	Screening assays for agonists or antagonists of receptor activat or of nf-kb
IL158152A0 (en)	2001-04-03	2004-03-28	Nestle Sa	Osteoprotegerin in milk
KR100427299B1 (en) *	2001-08-10	2004-04-14	한국생명공학연구원	Recombination plasmid pGHOPG(KCTC 1019BP) to produce human osteoprotegerin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6369027B1 (en) *	1995-12-22	2002-04-09	Amgen Inc.	Osteoprotegerin

2000
- 2000-08-29 AU AU69463/00A patent/AU6946300A/en not_active Abandoned
- 2000-08-30 CA CA002383043A patent/CA2383043A1/en not_active Abandoned
- 2000-08-30 WO PCT/US2000/023755 patent/WO2001016299A1/en active Application Filing

Also Published As

Publication number	Publication date
CA2383043A1 (en)	2001-03-08
WO2001016299A1 (en)	2001-03-08

Similar Documents

Publication	Publication Date	Title
HK1215265A1 (en)	2016-08-19	Treatment of tnf alpha related disorders tnf
AU5125400A (en)	2000-11-21	Methods for managing the distribution of client bits to client computers
AU2111500A (en)	2000-08-18	Bone tissue regenerating composition
AU2001242450A1 (en)	2001-09-17	Substances for the treatment of spinal muscular atrophy
AU7888801A (en)	2002-01-30	Use of 2-methylene-19-nor-20(s)-1alpha,25-dihydroxyvitamin D<sub>3</sub> to increase bone strength
AU9527001A (en)	2002-04-22	Treatment of T cell disorders
AU3110500A (en)	2000-06-19	Cell matrix plaques of initial bone formation
AU2683899A (en)	1999-09-06	The use of bjerknes forces to manipulate contrast agents
AU6946300A (en)	2001-03-26	Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders
AU2001256555A1 (en)	2001-12-24	New inhibotor of apoptosis of nerve cells
AU7104500A (en)	2001-03-26	Use of rafp to inhibit or prevent apoptosis
AU2003268484A1 (en)	2004-03-29	Delivery of therapeutics to the brain and spinal cord
AU2003239864A1 (en)	2003-12-12	Antisense moodulation of kinesin-like 1 expression
PL363921A1 (en)	2004-11-29	Skin moisturizing composition
AU2001255730A1 (en)	2001-11-07	Methods and compositions for the treatment of cardiac indications
HK1025894A1 (en)	2000-12-01	Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release.
GB0003048D0 (en)	2000-03-29	The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
AU4036199A (en)	1999-11-23	Stabilised compositions containing hyaluronic acid, their preparation and use
AU2003240446A1 (en)	2003-10-13	Use of mob-5 in pain
AU2003223070A1 (en)	2003-12-02	Obg3 fragments inhibiting the conversion of active obg3 into less active obg3 and other compositions for treatment of metabolic disorders
AU1354201A (en)	2001-05-14	Compositions and methods of synthesis and use of novel nucleic acid structures
AU2001255998A1 (en)	2001-11-26	Treatmentor prevention of metabolic bone disorder
AU2001253219A1 (en)	2001-10-15	Composition for treatment of autoimmune disease
AU2001271917A1 (en)	2002-01-21	Genes encoding sinapoylglucose: malate sinapoyltransferase and methods of use
AU2003206753A1 (en)	2003-07-30	Use of oxygen-enriched water

Legal Events

Date	Code	Title	Description
2002-05-16	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase